NAL 0.00% 0.6¢ norwood abbey limited

needle free injection vaccine breakthrough, page-11

  1. 356 Posts.
    The whole company currently only has a market capitalisation of $20m. It seems to me that just the veterinary market alone for a unique product like this that will make vaccinating large herds of animals faster, safer, easier and a lot more cost efficient. It would be worth a whole lot more than $20m to a large pharmaceutical co who could charge premium prices for such a unique product imo.

    There now seems to be no impediment to it's use on animals.

    Then there is the possibility of the human market....
 
watchlist Created with Sketch. Add NAL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.